Compare Stocks: CNAT, CARM, PTPI, and VINC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARM Carisma Therapeutics	$0.00 -12.0%	$0.01	$0.00 ▼ $0.56	$92K	-9.09	68,029 shs	111,675 shs
CNAT Conatus Pharmaceuticals	$0.00 +400.0%	$1.00	$0.23 ▼ $1.07	$41K	1.84	1.28 million shs	1,625 shs
PTPI Petros Pharmaceuticals	$0.00 +6.3%	$0.00	$0.00 ▼ $0.03	$106K	1.88	110,059 shs	47,812 shs
VINC Vincerx Pharma	$0.01	$0.01	$0.00 ▼ $0.07	$66K	1.44	5,262 shs	1,025 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARM Carisma Therapeutics	-12.00%	-12.00%	-57.69%	+2,100.00%	-99.25%
CNAT Conatus Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+316.67%
PTPI Petros Pharmaceuticals	+6.25%	+13.33%	-19.05%	-50.72%	-88.32%
VINC Vincerx Pharma	0.00%	0.00%	0.00%	-25.29%	-67.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARM Carisma Therapeutics	$0.00 -12.0%	$0.01	$0.00 ▼ $0.56	$92K	-9.09	68,029 shs	111,675 shs
CNAT Conatus Pharmaceuticals	$0.00 +400.0%	$1.00	$0.23 ▼ $1.07	$41K	1.84	1.28 million shs	1,625 shs
PTPI Petros Pharmaceuticals	$0.00 +6.3%	$0.00	$0.00 ▼ $0.03	$106K	1.88	110,059 shs	47,812 shs
VINC Vincerx Pharma	$0.01	$0.01	$0.00 ▼ $0.07	$66K	1.44	5,262 shs	1,025 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARM Carisma Therapeutics	-12.00%	-12.00%	-57.69%	+2,100.00%	-99.25%
CNAT Conatus Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+316.67%
PTPI Petros Pharmaceuticals	+6.25%	+13.33%	-19.05%	-50.72%	-88.32%
VINC Vincerx Pharma	0.00%	0.00%	0.00%	-25.29%	-67.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CARM Carisma Therapeutics	1.00	Sell	N/A	N/A
CNAT Conatus Pharmaceuticals	0.00	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	0.00	N/A	N/A	N/A
VINC Vincerx Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CARM Carisma Therapeutics	$10.77M	0.01	N/A	N/A	($0.67) per share	0.00
CNAT Conatus Pharmaceuticals	$21.72M	0.00	N/A	N/A	$0.53 per share	0.00
PTPI Petros Pharmaceuticals	$5.11M	0.02	N/A	N/A	$4.04 per share	0.00
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	$10.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CARM Carisma Therapeutics	-$60.48M	$0.73	0.00	N/A	N/A	-254.28%	N/A	-192.17%	N/A
CNAT Conatus Pharmaceuticals	-$11.39M	N/A	N/A	N/A	N/A	-52.42%	-48.22%	-39.32%	N/A
PTPI Petros Pharmaceuticals	-$8.16M	-$1.64	N/A	N/A	N/A	N/A	-78.22%	-23.50%	N/A
VINC Vincerx Pharma	-$40.16M	-$5.31	N/A	N/A	N/A	N/A	-248.33%	-132.73%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CARM Carisma Therapeutics	N/A	N/A	N/A	N/A	N/A
CNAT Conatus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PTPI Petros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CARM Carisma Therapeutics	N/A	0.48	0.48
CNAT Conatus Pharmaceuticals	N/A	16.28	16.28
PTPI Petros Pharmaceuticals	1.58	0.85	0.74
VINC Vincerx Pharma	N/A	2.17	2.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CARM Carisma Therapeutics	44.27%
CNAT Conatus Pharmaceuticals	15.20%
PTPI Petros Pharmaceuticals	12.34%
VINC Vincerx Pharma	44.02%

Insider Ownership

Company	Insider Ownership
CARM Carisma Therapeutics	6.90%
CNAT Conatus Pharmaceuticals	11.30%
PTPI Petros Pharmaceuticals	8.23%
VINC Vincerx Pharma	15.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CARM Carisma Therapeutics	20	41.85 million	38.91 million	No Data
CNAT Conatus Pharmaceuticals	30	33.17 million	N/A	Not Optionable
PTPI Petros Pharmaceuticals	20	31.16 million	9.93 million	Not Optionable
VINC Vincerx Pharma	60	5.23 million	1.89 million	Not Optionable

CNAT, CARM, PTPI, and VINC Headlines

Recent News About These Companies

Antibody Drug Conjugates (ADC) Market Research and Competitive Landscape Report 2026 - Extensive Analysis of Over 180 Companies and More Than 290 Drugs

April 14, 2026 | finance.yahoo.com

Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO)

January 18, 2026 | defenseworld.netD

Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...

July 16, 2025 | gurufocus.com

Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal

July 16, 2025 | globenewswire.com

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders | The ... - The Manila Times

July 9, 2025 | manilatimes.netM

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - Morningstar

July 9, 2025 | morningstar.comM

Vincerx Pharma, Inc. Common Stock (VINC) - Yahoo Finance

July 8, 2025 | finance.yahoo.com

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders

July 7, 2025 | globenewswire.com

Vincerx Pharma, Inc. (VINC) - Yahoo Finance

July 2, 2025 | ca.finance.yahoo.com

Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal

June 18, 2025 | globenewswire.com

Vincerx Pharma announces plan to delist from Nasdaq

April 18, 2025 | markets.businessinsider.com

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

April 17, 2025 | finance.yahoo.com

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

April 17, 2025 | globenewswire.com

Vincerx's final merger attempt collapses, leaving ADC biotech to wind down

April 9, 2025 | fiercebiotech.comF

Vincerx terminates letter of intent with Global Digital, initiates wind down

April 9, 2025 | markets.businessinsider.com

Financially struggling drugmaker's potential rescue falls apart. It now will wind down

April 9, 2025 | bizjournals.com

Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities

April 8, 2025 | globenewswire.com

Vincerx Pharma announces non-binding LOI for Qumulus AI combination

March 18, 2025 | markets.businessinsider.com

Vincerx Pharma, Inc.: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI

March 18, 2025 | finanznachrichten.de

Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis

March 18, 2025 | fiercebiotech.comF

New MarketBeat Followers Over Time

CNAT, CARM, PTPI, and VINC Company Descriptions

Carisma Therapeutics NASDAQ:CARM

$0.0022 0.00 (-12.00%)

As of 08/13/2026 03:45 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Conatus Pharmaceuticals NASDAQ:CNAT

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.

Petros Pharmaceuticals NASDAQ:PTPI

$0.0034 +0.00 (+6.25%)

As of 08/13/2026 03:57 PM Eastern

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Vincerx Pharma NASDAQ:VINC

$0.01 0.00 (0.00%)

As of 08/13/2026 03:35 PM Eastern

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Compare Profitability & Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNAT, CARM, PTPI, and VINC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

CNAT, CARM, PTPI, and VINC Company Descriptions

Carisma Therapeutics NASDAQ:CARM

Conatus Pharmaceuticals NASDAQ:CNAT

Petros Pharmaceuticals NASDAQ:PTPI

Vincerx Pharma NASDAQ:VINC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Compare Profitability & Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNAT, CARM, PTPI, and VINC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

CNAT, CARM, PTPI, and VINC Company Descriptions

Carisma Therapeutics NASDAQ:CARM

Conatus Pharmaceuticals NASDAQ:CNAT

Petros Pharmaceuticals NASDAQ:PTPI

Vincerx Pharma NASDAQ:VINC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools